Compare
Aclaris Therapeutics, Inc. vs Bolt Biotherapeutics, Inc. vs Adagene Inc. vs Xenon Pharmaceuticals Inc.
| Latest fiscal year | Aclaris Therapeutics, Inc. ACRS | Bolt Biotherapeutics, Inc. BOLT | Adagene Inc. ADAG | Xenon Pharmaceuticals Inc. XENE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $7.83M | $7.70M | $7.67M | $7.50M |
| Revenue growth (YoY) | -58.2% | +0.1% | n/m | n/a |
| Gross margin | 73.3% (computed) | n/a | n/a | n/a |
| Operating margin | -975.9% | -469.3% | -279.5% | n/m |
| Net margin | -829.6% | -433.7% | -229.6% | n/m |
| Net income | -$64.92M | -$33.38M | -$17.61M | -$345.91M |
| EPS (Diluted) | -$0.53 | -$17.85 | -$0.30 | -$4.36 |
| Operating cash flow | -$47.11M | -$39.85M | -$15.66M | -$279.12M |
| Free cash flow | -$47.22M | -$39.92M | -$15.67M | -$279.92M |
| Cash & equivalents | $19.96M | $11.70M | $74.52M | $199.16M |
| Total assets | $160.46M | $56.75M | $78.26M | $633.16M |
| Total liabilities | $57.38M | $30.24M | $26.36M | $51.40M |
| Shareholders' equity | $103.08M | $26.50M | $35.35M | $581.76M |
| Return on year-end equity | -63.0% | -125.9% | -49.8% | -59.5% |
| Shares outstanding | 120.50M | 1.92M | 59.23M | 80.01M |
Revenue, most recent five fiscal years
| Fiscal year | Aclaris Therapeutics, Inc. | Bolt Biotherapeutics, Inc. | Adagene Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|---|---|
| Latest | $7.83M Ended 2025-12-31 | $7.70M Ended 2025-12-31 | $7.67M Ended 2025-12-31 | $7.50M Ended 2025-12-31 |
| 1 year earlier | $18.72M Ended 2024-12-31 | $7.69M Ended 2024-12-31 | $103.2K Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | $31.25M Ended 2023-12-31 | $7.88M Ended 2023-12-31 | $18.11M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $29.75M Ended 2022-12-31 | $5.73M Ended 2022-12-31 | $9.29M Ended 2022-12-31 | $9.43M Ended 2022-12-31 |
| 4 years earlier | $6.76M Ended 2021-12-31 | $1.26M Ended 2021-12-31 | $10.18M Ended 2021-12-31 | $18.44M Ended 2021-12-31 |